Search Results - "BECA, J"

Outcomes Following Treatment with FOLFOX for Patients with Resectable or Potentially Resectable Metastatic Colorectal Cancer: A Population-based Cohort Study by Habbous, S., Tai, X., Gill, T., Arias, J., Beca, J., Raphael, M.J., Kennedy, E., Biagi, J.J., Chan, K.K.W.

“…To evaluate the safety and effectiveness of oxaliplatin-based combination chemotherapy for patients with metastatic colorectal cancer (mCRC) to extrahepatic…”
Get full text

Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival by Dai, W.F., Habbous, S., Saluja, R., Beca, J.M., Raphael, M., Arias, J., Gavura, S., Earle, C.C., Biagi, J.J., Coburn, N., Chan, K.K.W.

“…First-line FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan, and OXaliplatin) and gemcitabine plus nab-paclitaxel (GnP) have been publicly funded for…”
Get full text

Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces by Beca, J.M., Dai, W.F., Pataky, R.E., Tran, D., Dvorani, E., Isaranuwatchai, W., Peacock, S., Alvi, R., Cheung, W.Y., Earle, C.C., Gavura, S., Chan, K.K.W.

“…To examine the real-world safety of adding bevacizumab to first-line irinotecan-based chemotherapy for patients with metastatic colorectal cancer (mCRC)…”
Get full text

Cost-effectiveness of Intensity-modulated Radiotherapy in Prostate Cancer by Yong, J.H.E, Beca, J, McGowan, T, Bremner, K.E, Warde, P, Hoch, J.S

“…Abstract Aims To compare the costs and effectiveness of intensity-modulated radiotherapy (IMRT) with three-dimensional conformal radiotherapy (3DCRT) for the…”
Get full text

Exploring the impact of structural uncertainty in partitioned survival models for oncology by Beca, J, Hoch, J.S

Get full text

Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario by Yong, J H E, McGowan, T, Redmond-Misner, R, Beca, J, Warde, P, Gutierrez, E, Hoch, J S

“…Radiotherapy is a common treatment for many cancers, but up-to-date estimates of the costs of radiotherapy are lacking. In the present study, we estimated the…”
Get full text

Cost-effectiveness of Intensity-modulated Radiotherapy in Oropharyngeal Cancer by Yong, J.H.E, Beca, J, O'Sullivan, B, Huang, S.H, McGowan, T, Warde, P, Hoch, J.S

“…Abstract Aims Intensity-modulated radiotherapy (IMRT) is an advanced radiation technique that is particularly suited to treating head and neck cancers because…”
Get full text

Catastrophic left heart distension following initiation of venoarterial extracorporeal membrane oxygenation in a patient with mild aortic regurgitation by Sidebotham, D, Allen, S, McGeorge, A, Beca, J

Get full text

Impact of a novel prioritization framework on clinician-led oncology drug submissions by Keech, J, Beca, J, Eisen, A, Kennedy, E, Kim, J, Kouroukis, C T, Darling, G, Ferguson, S E, Finelli, A, Petrella, T M, Perry, J R, Chan, K, Gavura, S

“…In Canada, requests for public reimbursement of cancer drugs are predominately initiated by pharmaceutical manufacturers. Clinician-led submissions provide a…”
Get full text

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada by Djalalov, S, Beca, J, Amir, E, Krahn, M, Trudeau, M E, Hoch, J S

“…Aromatase inhibitor (ai) therapy has been subjected to numerous cost-effectiveness analyses. However, with most ais having reached the end of patent protection…”
Get full text

Extracorporeal membrane oxygenation for cardiorespiratory failure in four patients with pandemic H1N1 2009 influenza virus and secondary bacterial infection by Buckley, E., Sidebotham, D., McGeorge, A., Roberts, S., Allen, S.J., Beca, J.

“…We report four patients with pandemic H1N1 2009 influenza virus and secondary bacterial infection who were treated with extracorporeal membrane oxygenation…”
Get full text

Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals by Beca, J, Chan, K K W

“…We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma…”
Get full text

The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario by Djalalov, S, Graham, D.M, Beca, J, Hoch, J.S, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer by Djalalov, S, Graham, D.M, Beca, J, Hoch, J.S, Tsao, M.S, Leighl, N

Get full text

Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada) by Djalalov, S, Beca, J, Hoch, J.S, Krahn, M.D, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

PCN67 Economic Evaluation of Mono and Sequential Hormone Therapies for ER+ Women With Early Breast Cancer in Canada by Djalalov, S, Beca, J, Li, B, Krahn, M, Hoch, J

Get full text

PCN87 Cost-Effectiveness of Hormone Therapies for ER+ Women with Early Breast Cancer in Canada: Exploring the Potential for the Cyp2D6 Genetic Test by Djalalov, S, Beca, J, Li, B, Krahn, M, Hoch, J.S

Get full text

Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario by Djalalov, S, Hoch, J.S, Beca, J, Krahn, M, Tsao, M.S, Cutz, J.C, Leighl, N

Get full text

PCN58 IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR ER+ HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-EFFECTIVE? by Djalalov, S, Beca, J, Hoch, J

Get full text

PMH31 Genetic Testing in Combination With Preventive Donepezil Treatment for Amnestic Mild Cognitive Impairment Patients: An Exploratory Economic Evaluation of Personalized Medicine by Djalalov, S, Yong, J, Beca, J, Black, S, Saposnik, G, Musa, Z, Siminovitch, K, Moretti, M, Hoch, J

Get full text